Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.70
-0.54 (-4.80%)
At close: Apr 14, 2026, 4:00 PM EDT
11.07
+0.37 (3.42%)
After-hours: Apr 14, 2026, 6:56 PM EDT
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+66.17%
P/S Ratio
4.65
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.25% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.89% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 1.03B |
| Corcept Therapeutics | 761.41M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
TLX News
- 1 hour ago - Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma - GlobeNewsWire
- 1 day ago - Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
- 1 day ago - Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
- 1 day ago - Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals - GuruFocus
- 1 day ago - Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies - Nasdaq
- 1 day ago - Telix and Regeneron Announce Strategic Radiopharma Collaboration - GlobeNewsWire
- 1 day ago - Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies - Nasdaq
- 4 days ago - Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum - International Business Times (Australia)